Inhibition of c-Met as a Therapeutic Strategy for Esophageal Adenocarcinoma

Inhibition of c-Met as a Therapeutic Strategy for Esophageal Adenocarcinoma

The hepatocyte growth factor (HGF) receptor c-Met is a tyrosine kinase receptor with established oncogenic properties. We have previously shown that c-Met is usually overexpressed in esophageal adenocarcinoma (EA), yet the implications of c-Met inhibition in EA remain unknown. Three c-Met-overexpres...

Full description

Bibliographic Details
Main Authors: Gregory A. Watson, Xinglu Zhang, Michael T. Stang, Ryan M. Levy, Pierre E. Queiroz de Oliveira, William E. Gooding, James G. Christensen, Steven J. Hughes
Format: Article
Language:English
Published: Elsevier 2006-11-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
c-Met
hepatocyte growth factor (HGF)
PHA665752
phosphatidylinositol 3-kinase (PI3K)
extracellular regulated kinase (ERK)
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558606800795

Internet

http://www.sciencedirect.com/science/article/pii/S1476558606800795

Similar Items